Early & Late-Stage Venture Capital

With over 30 years of experience investing in novel life science technologies, we understand how challenging it can be to turn a great idea into a great company.

We are comfortable evaluating and taking significant scientific risks. Our team and network of advisors includes a number of former executives with first-hand experience of these challenges, who are available to provide support and advice when it is needed.

We also understand that building a successful company takes time and patience. Our team is committed to building real value over the long-term.

38product approvals
52M&A / exits
40+technical experts
65IPOs

"As one of Tizona’s early investors, Abingworth has been a very engaged partner, providing support and prodigious resources to the company. They also bring a deep knowledge of the industry and an extensive network that has benefited us greatly."

Pablo Cagnoni, CEO of Tizona Therapeutics

"I was impressed by Abingworth’s thoughtful, candid and rigorous diligence process, and their interest in building a relationship with management before they became investors. That approach created mutual understanding and trust, and laid the foundation for a highly productive partnership."

Timothy Noyes, President and CEO of Proteon Therapeutics

"Abingworth not only devised and executed a thorough diligence process, but as our lead Series A investor, galvanized a strong long-term investor syndicate. Through their expansive network, they also helped us secure the site of our new corporate headquarters in an intensely competitive real estate market."

Grant Pickering, President and CEO of SutroVax

"I feel fortunate to have Abingworth as an investor in Wilson Therapeutics. Their in-depth knowledge of drug development in combination with being very well connected in the life science industry adds great value to our company."

Jonas Hansson, CEO of Wilson Therapeutics

"Abingworth was the first institutional investor to reach out directly to VenatoRx, even before we were looking to fund-raise. They have excellent knowledge of the infectious disease domain space and had clearly done their homework. We enjoy a strong collaborative relationship that adds significant value to the company."

Christopher Burns, CEO of VenatoRx